High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience

Cancer
Giuseppe Maria MilanoAlberto Donfrancesco

Abstract

Ewing sarcoma (ES) and extraosseous ES/primitive neuroectodermal tumors (PNET) share histopathologic features of the ES family of tumors (ESFT). The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT. Since 1990, patients with ESFT and with 1 or more of the following risk factors were reviewed: tumor volume > 200 mL, tumor site with a poor prognosis, and pulmonary and/or bone marrow metastases. Thirty-six patients with ESFT who were involved in the study were divided into 2 arms of 18 patients each. One group received treatment with various regimens, and the other group received treatment with ICE plus CAV. The disease was brought under control more rapidly in the latter patients, for whom surgery was more easily feasible, and up to 90% of patients achieved a major response, with an estimated 3-year overall survival rate of 67% +/- 12%. The current results showed that ICE plus CAV was tolerated well and was effective in the studied subset of tumors, indicating that dose intensification correlates with better disease control, a high percentage of necrosis, and conservative sur...Continue Reading

References

Sep 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E O BurgertP Thomas
Nov 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S MiserE Glatstein
Jul 1, 1988·International Journal of Radiation Oncology, Biology, Physics·S L SailerH D Suit
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·V GöbelU Göbel
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B H KushnerG Heller
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P ScullyM C Gebhardt
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K K FieldsG J Elfenbein
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P PicciP Ruggieri
Jan 1, 1993·The American Journal of Surgical Pathology·L P Dehner
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N M MarinaW Meyer
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B RaneyH M Maurer
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P PicciF Bertoni
May 29, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PaulussenH Jürgens
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M PaulussenH Jürgens
Apr 29, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I ElomaaT A Alvegård
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J CotterillA W Craft
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C R PinkertonT Philip
Sep 25, 2001·Medical and Pediatric Oncology·R D JenkinH P Schultz
May 9, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M Abu-GhoshM S Cairo
Sep 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Anders KolbPaul A Meyers

❮ Previous
Next ❯

Citations

Jul 31, 2013·Journal of Pediatric Hematology/oncology·Antonino TrizzinoPaolo D'Angelo
Feb 6, 2013·PloS One·Maria Antonietta De IorisRoberto Luksch
Feb 25, 2014·Journal of Translational Medicine·Maria Debora De PasqualeRenata Boldrini
Jul 21, 2012·Journal of Pediatric Surgery·Alessandro CrocoliFrancesco Morini
Apr 29, 2015·Pediatric Blood & Cancer·Algemir L BrunettoUNKNOWN Brazilian Collaborative On behalf of the Brazilian Collaborative Study Group of Ewing Family of Tumors EWING1 and the Brazil
Jun 1, 2014·BBA Clinical·Federica SalettaJennifer A Byrne
Jul 31, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Massimo BergerRoberto Luksch
Nov 14, 2015·World Journal of Clinical Pediatrics·Surasak Sangkhathat
Nov 1, 2012·Thoracic Cancer·Shinya TaneMasahiro Yoshimura
Oct 17, 2020·Indian Journal of Thoracic and Cardiovascular Surgery : Official Organ, Association of Thoracic and Cardiovascular Surgeons of India·Saipavan AnneGopal Palanki
Feb 25, 2021·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Alberto RighiAngelo Paolo Dei Tos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.